{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:29:06Z","timestamp":1789612146557,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.cllc.2025.10.018","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T02:10:20Z","timestamp":1761185420000},"page":"38-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Savolitinib Plus Osimertinib in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial"],"prefix":"10.1016","volume":"27","author":[{"given":"James Chih-Hsin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuh-Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ullas","family":"Batra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kien Hung","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyada","family":"Sitthideatphaiboon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pongwut","family":"Danchaivijitr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang-Yun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarin","family":"Chindaprasirt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Ta","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gee-Chen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaiyut","family":"Charoentum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teerapat","family":"Ungtrakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Ignacio Hernandez","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Hartmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ike","family":"Igwegbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Gont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Haskins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanning","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Riess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.cllc.2025.10.018_bib0001","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.cllc.2025.10.018_bib0002","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum\u2013pemetrexed in EGFR T790M\u2013positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cllc.2025.10.018_bib0003","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.cllc.2025.10.018_bib0004","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.cllc.2025.10.018_bib0005","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non\u2013small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.cllc.2025.10.018_bib0006","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1200\/JCO-24-02785","article-title":"Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO Living Guideline, version 2024.3","volume":"43","author":"Owen","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.cllc.2025.10.018_bib0007","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"ESMO oncogene-addicted metastatic non-small-cell lung cancer living guideline, v1.2 January 2025","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.cllc.2025.10.018_bib0008","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"issue":"7 Suppl","key":"10.1016\/j.cllc.2025.10.018_bib0009","doi-asserted-by":"crossref","first-page":"S1420","DOI":"10.1016\/j.annonc.2022.08.055","article-title":"LBA53 ELIOS: a multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib","volume":"33","author":"Piotrowska","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2025.10.018_bib0010","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat Commun"},{"issue":"16 Suppl","key":"10.1016\/j.cllc.2025.10.018_bib0011","doi-asserted-by":"crossref","first-page":"9074","DOI":"10.1200\/JCO.2023.41.16_suppl.9074","article-title":"Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib","volume":"41","author":"Yu","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.cllc.2025.10.018_bib0012","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.annonc.2025.04.003","article-title":"Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and\/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study","volume":"36","author":"de Marinis","year":"2025","journal-title":"Ann Oncol"},{"issue":"609","key":"10.1016\/j.cllc.2025.10.018_bib0013","doi-asserted-by":"crossref","first-page":"eabb3738","DOI":"10.1126\/scitranslmed.abb3738","article-title":"Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer","volume":"13","author":"Eser","year":"2021","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.cllc.2025.10.018_bib0014","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40164-021-00245-y","article-title":"MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors","volume":"10","author":"Peng","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.cllc.2025.10.018_bib0015","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2147\/OTT.S329095","article-title":"Amivantamab in the treatment of metastatic NSCLC: patient selection and special considerations","volume":"15","author":"Petrini","year":"2022","journal-title":"Onco Targets Ther"},{"issue":"1","key":"10.1016\/j.cllc.2025.10.018_bib0016","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.cllc.2025.10.018_bib0017","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1021\/jm500510f","volume":"57","author":"Jia","year":"2014","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.cllc.2025.10.018_bib0018","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.molonc.2014.08.015","article-title":"Volitinib, a potent and highly selective c-met inhibitor, effectively blocks c-met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models","volume":"9","author":"Gavine","year":"2015","journal-title":"Mol Oncol"},{"issue":"16","key":"10.1016\/j.cllc.2025.10.018_bib0019","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.1158\/1078-0432.CCR-18-1189","article-title":"First-in-human phase I study of the selective MET inhibitor, savolitinib, in patients with advanced solid tumors: safety, pharmacokinetics, and antitumor activity","volume":"25","author":"Gan","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"15 Suppl","key":"10.1016\/j.cllc.2025.10.018_bib0020","doi-asserted-by":"crossref","first-page":"CT305","DOI":"10.1158\/1538-7445.AM2015-CT305","article-title":"CT305: phase I studies of a selective cMet inhibitor AZD6094 (HMPL504\/volitinib) in patients with advanced solid tumors","volume":"75","author":"Hua","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.cllc.2025.10.018_bib0021","unstructured":"HUTCHMED. HUTCHMED announces NMPA full approval for ORPATHYS\u00ae (savolitinib) in China for patients with locally advanced or metastatic MET exon 14 NSCLC. https:\/\/www.hutch-med.com\/nmpa-full-approval-for-orpathys-savolitinib-for-met14-nsclc\/ (accessed 14 January 2025)."},{"issue":"10","key":"10.1016\/j.cllc.2025.10.018_bib0022","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S2213-2600(21)00084-9","article-title":"Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study","volume":"9","author":"Lu","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"5827","key":"10.1016\/j.cllc.2025.10.018_bib0023","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.cllc.2025.10.018_bib0024","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2009.11.022","article-title":"Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC","volume":"17","author":"Turke","year":"2010","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.cllc.2025.10.018_bib0025","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1158\/1535-7163.MCT-12-0195","article-title":"Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer","volume":"11","author":"Nakagawa","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.cllc.2025.10.018_bib0026","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1158\/2159-8290.CD-22-0586","article-title":"Osimertinib + savolitinib to overcome acquired MET-mediated resistance in epidermal growth factor receptor-mutated, MET-amplified non-small cell lung cancer: TATTON","volume":"13","author":"Hartmaier","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cllc.2025.10.018_bib0027","doi-asserted-by":"crossref","unstructured":"Yu HA, Ambrose H, Baik C, et al. ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib. Presented at ESMO 2021 [Poster 3222].","DOI":"10.1016\/j.annonc.2021.08.1844"},{"issue":"3","key":"10.1016\/j.cllc.2025.10.018_bib0028","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1470-2045(19)30785-5","article-title":"Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study","volume":"21","author":"Sequist","year":"2020","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.cllc.2025.10.018_bib0029","doi-asserted-by":"crossref","first-page":"S469","DOI":"10.1016\/j.jtho.2022.07.823","article-title":"EP08.02-140 MET biomarker-based preliminary efficacy analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC post-osimertinib","volume":"17","author":"Ahn","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2025.10.018_bib0030","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12931-023-02329-1","article-title":"Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer","volume":"24","author":"Yao","year":"2023","journal-title":"Respir Res"},{"issue":"8","key":"10.1016\/j.cllc.2025.10.018_bib0031","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(24)00270-5","article-title":"Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial","volume":"25","author":"Wu","year":"2024","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.cllc.2025.10.018_bib0032","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1158\/1078-0432.CCR-22-3146","article-title":"Early clearance of plasma epidermal growth factor receptor mutations as a predictor of outcome on osimertinib in advanced non-small cell lung cancer; exploratory analysis from AURA3 and FLAURA","volume":"29","author":"Gray","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"17 Suppl","key":"10.1016\/j.cllc.2025.10.018_bib0033","first-page":"LBA8505","volume":"43","author":"Lu","year":"2025","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.cllc.2025.10.018_bib0034","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jamaoncol.2020.2218","article-title":"Efficacy of savolitinib vs sunitinib in patients with MET-driven papillary renal cell carcinoma: the SAVOIR phase 3 randomized clinical trial","volume":"6","author":"Choueiri","year":"2020","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.cllc.2025.10.018_bib0035","first-page":"S468","article-title":"EP08.02-138 SAFFRON: Ph3 savolitinib + osimertinib vs chemotherapy in EGFRm NSCLC with MET overexpression\/amplification post-osimertinib","volume":"17","author":"Lu","year":"2022","journal-title":"J Thorac Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425002803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425002803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:20:55Z","timestamp":1773865255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730425002803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1525730425002803"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2025.10.018","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Savolitinib Plus Osimertinib in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2025.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}